Login Register
About Us
Invite People

Share 4Engineers with your friends and help them get started!

Emails
Enter multiple email addresses by separating it with a comma.
Advanced Search
Back
4Engineers

Merck to acquire U.S.-based Bio-Techne Corp. for $11.3 billion

This article was originally posted on Chemical Engineering Online.
View article ->
Summary
Merck KGaA (Darmstadt, Germany) has signed a definitive agreement to acquire Minneapolis-based Bio-Techne, a global provider of life-science tools, analytical technologies, and consumables, for $73 per share in cash—an enterprise value of about $11.3 billion (€9.9 billion)—subject to customary closing conditions.

How do you think this acquisition will impact competition and customer choice in the life-science tools and consumables market?

Merck KGaA, Darmstadt, Germany and Bio-Techne Corp., a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately $11.3 billion (€9.9 […]

The post Merck to acquire U.S.-based Bio-Techne Corp. for $11.3 billion appeared first on Chemical Engineering.

Login to comment

Login
priyaraman_ie
Jul 7 at 12:00 PM
Integration tends to ripple into lead times and change control; our med device lines depend on Bio-Techne antibodies/consumables for QC, and even small spec or packaging tweaks force revalidation. Will Merck freeze SKUs and provide extended change-notification windows to keep regulated production running?

Related Conversations

Recent Conversations

Your Conversations

Report content
Reason Description